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Background: Rhodiola crenulata (R. crenulata) is widely used to prevent acute mountain sickness in the Himalayan
areas and in Tibet, but no scientific studies have previously examined its effectiveness. We conducted a randomized,
double-blind, placebo-controlled crossover study to investigate its efficacy in acute mountain sickness prevention.
Methods: Healthy adult volunteers were randomized to 2 treatment sequences, receiving either 800 mg R. crenulata
extract or placebo daily for 7 days before ascent and 2 days during mountaineering, before crossing over to the
alternate treatment after a 3-month wash-out period. Participants ascended rapidly from 250 m to 3421 m on two
separate occasions: December 2010 and April 2011. The primary outcome measure was the incidence of acute
mountain sickness, as defined by a Lake Louise score≥ 3, with headache and at least one of the symptoms of nausea
or vomiting, fatigue, dizziness, or difficulty sleeping.
Results: One hundred and two participants completed the trial. There were no demographic differences between
individuals taking Rhodiola-placebo and those taking placebo-Rhodiola. No significant differences in the incidence of
acute mountain sickness were found between R. crenulata extract and placebo groups (all 60.8%; adjusted odds ratio
(AOR) =1.02, 95% confidence interval (CI) =0.69–1.52). The incidence of severe acute mountain sickness in Rhodiola
extract vs. placebo groups was 35.3% vs. 29.4% (AOR = 1.42, 95% CI = 0.90–2.25).
Conclusions: R. crenulata extract was not effective in reducing the incidence or severity of acute mountain sickness as
compared to placebo.
Trial registration: ClinicalTrials.gov NCT01536288.
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Acute mountain sickness (AMS) occurs in individuals
rapidly ascending to high altitude and it usually results
in headache, along with anorexia or nausea, fatigue, dizzi-
ness, and insomnia [1]. The number of people travelling
rapidly to higher altitudes for work or recreation is rising.
As a result of improvements in transportation to these
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reproduction in any medium, provided the orenvironmental health issue [2]. The most effective prevent-
ive method for AMS—gradual ascent—is usually difficult
or impractical for modern international travelers to loca-
tions such as Lhasa in Tibet (3650 m) and La Paz in Bolivia
(3740 m) [3]. The pathophysiology of AMS is not totally
understood but it is apparent that administration of
prophylactic treatments is helpful. Historically acetazol-
amide has been used as a gold standard in treatments to
prevent malaise symptoms at high altitudes [1,2,4-7].
However, acetazolamide requires a prescription and has
side effects such as paresthesia, dysgeusia, and diuresis
[2,8,9]. Some over-the-counter herbal supplements such
as Rhodiola species, Ginkgo biloba and Coca leaf products
are widely used [3,5,7,10-17].d. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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medical plant in European countries for thousands of years
[10,18,19]. There are more than ninety species worldwide
and they are well known for their high antioxidant activ-
ities. Different species of Rhodiola differ in their content
of bioactive components and medicinal use in indigenous
regions. To date, most studies focus on the efficacy of
Rhodiola rosea in treating physical and mental fatigue.
Of all the known Rhodiola species, Rhodiola crenulata
(R. crenulata) is particularly described in the Pharmacopoeia
of China [16] and is considered as the highest in quality.
Also, it has been used for treating acute mountain sickness
in Tibet since ancient times [20].
Pulmonary alveolar hypoxia, a common phenomenon
for non-acclimatized individuals who abruptly relocate to
a high altitude, is thought to contribute to the impaired
trans-alveolar fluid transport. The excessive fluid that
subsequently accumulates in alveoli exaggerates alveolar
hypoxia and obstructs the gas exchange process, leading
to the pathological progression of high altitude pulmonary
edema, the most lethal form of high-altitude illnesses
[21,22]. In a rodent model, R. crenulata extract exhibited
a high antioxidant activity and attenuated pulmonary
edema induced by hypobaric hypoxia [20]. Recent studies
have shown that Na/K-ATPase plays a key role in alveolar
fluid clearance. Both inhibition and knockdown of Na/K-
ATPase expression significantly reduced the alveolar fluid
clearance in rodent models [23,24]. Two bioactive compo-
nents of R. crenulata, salidroside and tyrosol, were shown
to hold antioxidant, anti-depression, anti-fatigue, and anti-
inflammatory activities [25-30]. Therefore, the capabilities
of R. crenulata in preventing the hypoxia-mediated Na/
K-ATPase endocytosis and maintaining the integrity of
alveolar-capillary barrier and pulmonary sodium transport
might be the underlying mechanisms of its effect against
pulmonary edema in rodent models [31].
Although R. crenulata is widely used to prevent AMS in
the Himalayan areas and in Tibet [20,32], but no scientific
studies have examined its effectiveness in humans. We
conducted a controlled study to investigate the efficacy of
R. crenulata in AMS prevention. In the clinical trials for
Rhodiola, most studies were conducted to investigate
whether Rhodiola could improve the endurance exercise
performance or protect against fatigue. The daily dosage
of Rhodiola extract tested was mostly under 500 mg
(ranged between 100–972 mg) [15,18,19]. Regarding the
duration of prophylactic medication for AMS, chemical
drugs such as acetazolamide could elicit a quick response
and were usually administered on the day before or prior
to the ascent. In the trials on AMS prevention using
prophylactic herbal medication, Ginkgo biloba was the
one mostly studied. It was often administered for one to
five days prior to the ascent [3,11-13]. Considering the on-
set of AMS after ascent and the compliance of prophylacticmedication, a high dose of R. crenulata (800 mg daily) was
chosen in this study and the subjects were administered
with R. crenulata for seven days prior to the ascent.
Methods
Ethics statement
This study has been approved by the Institutional Review
Board (IRB) of Chang Gung Medical Foundation, Linkou
Medical Center, Taoyuan, Taiwan. The IRB approved
number is “99-3057C” and the topic is titled “Can Rhodiola
Crenulata Intake Improve Oxygen Saturation and Decrease
the Incidence of Acute Mountain Sickness”. Subjects were
given written information and a verbal explanation con-
cerning the study prior to obtaining the written informed
consent for their participation.
Subjects
We included local Chinese adults aged 23 to 55 years who
resided principally at an elevation of 250 m or lower. We
excluded those who (1) would not complete the study
protocol of two 9-day treatment courses; (2) had prophy-
lactic medication or herbs one month before each ascent
(including acetazolamide, sildenafil, tadalafil, dexametha-
sone, nifedipine, Rhodiola species, Ginkgo biloba, Eleuthero
Root, Salvia miltiorrhiza, and sea buckthorn); (3) change
in altitude of residence for more than 200 m between as-
cents; (4) had additional physical training or were sched-
uled to gain or lose weight; (5) had altitude exposure above
2500 m within three months prior to each ascent; (6) had
any history of chronic obstructive pulmonary disease, heart
failure, cerebral neoplasm, mania, renal or hepatic insuf-
ficiency; or (7) were pregnant or intended to become
pregnant during the 3-month study period. After base-
line assessment, the subjects were randomly assigned
into either sequence.
Study design, randomization and blinding
This study was a randomized, double-blind, placebo-
controlled and crossover trial. Subjects were randomized
to 2 treatment sequences, receiving either the R. crenulata
or the placebo, and then crossed over to the alternate
treatment after a 3 month wash-out period. Random num-
bers were generated by using the computer, using block
randomization with a block size of 2 or 4. The random
numbers were placed in sealed envelopes, and a serial
number was assigned to each envelope according to the
sequence of allocation of the randomized number. Each
envelope was then opened sequentially, according to the
admission sequence of the participants at the study center.
The number inside the envelope determined the treatment
sequence that each participant was allocated to (Rhodiola-
placebo or placebo-Rhodiola). Both investigators and
participants were blinded. One investigator, who was not
responsible for any assessment, enrolled all participants
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until the data analysis was complete.
Medications
Commercial pharmaceutical grade R. crenulata and placebo
were packed by Kaiser Pharmaceutical & Biotanico (Tainan,
Taiwan). Both were pink soft gelatin capsules (400 mg/
capsule) in identical containers and there were no differ-
ences in the taste or smell of the capsules. The standard-
ized R. crenulata extract (with 2.38% salidroside and 0.44%
p-tyrosol) was manufactured from the same batch of raw
materials [33,34]. The origin of the herb was authenticated
by microscopic identification and sequence analysis of
the internal transcribed spacer regions. The material was
examined for microorganisms, heavy metals, and pesticide
according to the accepted standards (good manufacturing
practice, GMP) of Taiwan. Each participant received a
high dose (800 mg) of R. crenulata or placebo (800 mg)
daily for 9 days. Beginning 7 days before an ascent, partici-
pants were required to inform the investigators by email
or telephone every day about the study capsule supply or
any adverse effects. If the investigators were not contacted
before noon, they would follow up by phone to obtain this
information. Moreover, the participants were requested to
take capsules every morning of their 2-day mountaineering
trip.
Ascent
To control the ascent rate, participants were transported
by bus from an altitude of 250 m to 3100 m (the training
camp) within 4 h (Figure 1); they rested for 2 h, hiked
1 km to the East Peak (3421 m, 24°N 121°E) of HehuanFigure 1 Mountaineering schedule. Total of 10 checkpoints (CPs): CP 1, L
(2756 m); 4, training camp (3100 m) at noon; 5, East Peak (3421 m) of Hehu
morning); 8, Main Peak (3416 m) of Hehuan Mountain; 9, Cingjing Farm an
by bus.Mountain, Taiwan within 1.5 h, rested 30 min, and des-
cended back to the training camp (3100 m), where they
remained overnight. On the second day, all participants
were transported by bus to the entrance (3200 m) of the
main peak of Hehuan Mountain, and they went hiking
along the easy trekking path to the peak (3416 m). After
that, they returned to the entrance of the main peak and
traveled back to Linkou by bus. There were 10 checkpoints
for assessment, namely, Linkou (250 m), Cingjing Farm
(1743 m), Yuanfeng parking lot (2756 m), training camp
(3100 m), the East Peak (3421 m) of Hehuan Mountain,
training camp in the evening and morning, the Main Peak
(3416 m) of Hehuan Mountain, Cingjing Farm, and
Linkou. During the mountaineering trips, the following
variables were controlled: rate of ascent, path, food type,
and sleep altitude/environment. The training camp could
not accommodate all subjects at once. Thus, the partici-
pants were divided into 2 groups in each period, and they
ascended separately in less than 10 days apart. The usual
snow season of the Hehuan Mountain is between early
January and early March. We chose early and mid-
December 2010, late March, and early April 2011 as our 4
mountaineering dates. The atmospheric pressure and
temperature were recorded at each checkpoint during
every trip.
Measurements
The Lake Louise scoring system (LLS)—a simple and
widely accepted tool developed by the Lake Louise Con-
sensus Group [1,35]—was used to assess the AMS grade.
The LLS rates 5 symptoms (headache, gastrointestinal
symptoms such as nausea and vomiting, fatigue and/orinkou (250 m); 2, Cingjing Farm (1743 m); 3, Yuanfeng parking lot
an Mountain; 6, training camp (evening); 7, training camp (next
d 10, Linkou. Solid line indicates that participants were transported
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sleeping) on a self-report questionnaire, with each item
graded on a scale from 0 to 3. Thus, the LLS scores can
range from 0 (no symptoms or signs) to 15 (the worst
rating on each symptom) [12,13,35].
The AMS grade, Lake Louise self-report questionnaire,
and pulse oximetry (SpO2, NPB 40, Nellcor, Pleasanton,
CA, USA) were completed at 10 checkpoints along the
route. Four emergency physicians, familiar with the
management of AMS, took care of any discomfort of the
participants during the whole course of mountaineering.
Participants were not permitted to self-treat their AMS
symptoms. Instead, they were told in advance that investi-
gators would provide oral acetaminophen (500 mg) or
ibuprofen (400 mg) for headache, meclizine (25 mg) for
dizziness or intramuscular prochlorperazine (5 mg) for
nausea and/or vomiting.
All subjects had their own mountaineering health
passport. It had a list of symptoms related to AMS, advice
and precautions to take during mountaineering, a place
to record pulse oximetry values, and the Lake Louise
questionnaire (to be filled out at each checkpoint). It was
also used to record clinical problems and treatment.
Outcomes
The predetermined primary outcome was the incidence
of AMS. It was evaluated at checkpoints 3 to 8 (altitude
above 2500 m) or at any time of discomfort after ascent.
AMS was defined as LLS score ≥ 3 with headache and at
least one of the symptoms of nausea or vomiting, fatigue,
dizziness, or difficulty sleeping. Predetermined secondary
outcomes included incidence of severe acute mountain
sickness (LLS score ≥ 5), incidence of headache and severe
headache (defined as a headache score of 2 or 3 on the
headache item of LLS), oxygen saturation by pulse oximetry
(SpO2) at checkpoint 4 (3100 m) and its difference between
altitudes 250 m and 3100 m (ΔSpO2: SpO2 measured at
checkpoint 1 minus SpO2 at checkpoint 4).
Sample size
The incidence of AMS in placebo group was hypothesized
as 36% according to our previous survey [36]. A relative
risk reduction of 30% was considered the clinically signifi-
cant effect in this type of treatment. According to the
study design, assuming the absence of carry-over or period
effects, a sample size of 133 participants was deemed suffi-
cient to provide a power of 80% with a two-sided alpha
level of 0.1 and a probability of discordant pairs of 0.7 to
detect an odds ratio for the incidence of AMS of 0.59
between the Rhodiola group and the placebo group.
Statistical methods
Baseline characteristics are presented as mean ± SD (stand-
ard deviation) or counts (percentages), as appropriate. Foreach variable, participants were grouped according to se-
quence (Rhodiola-placebo or placebo-Rhodiola) to make
the baseline comparison. Comparisons between the two
sequences were analyzed by the two-sample independent t
test for continuous variables and Chi-square test/ Fisher
exact test for categorical variables. Carry-over effects and
period effects were assessed using the generalized linear
models with generalized estimating equations, assuming a
logit link function and an unstructured correlation.
If neither a period nor a carry-over effect occurred,
paired t test or McNemar test was used to test the treat-
ment effect. Otherwise, the generalized linear models with
generalized estimating equations were used to analyze the
treatment effect, assuming a logit link function and an un-
structured correlation for binary outcomes or an identity
link function and an unstructured correlation for continu-
ous outcomes, and assuming adjustment for period and
carry-over effects in the model. All statistical assessments
were evaluated at a two-sided significance level of 0.05.
Analyses were performed with SAS software package,
version 9.2 (SAS Institute Inc., Cary, NC, USA).Results
Participants
All 125 participants were recruited to the study in
November 2010, and they made two separate trips to
Hehuan Mountain: one in early or mid-December 2010
and one in April 2011 or early May. On the second trip,
the ascent of one half of the participants was terminated
midway (1740 m) because of an unexpected snow storm
in late March 2011. Another trip was rescheduled to early
May 2011. The trial flow diagram is shown in Figure 2.
In all, 23 participants withdrew: 5 from the Rhodiola–
placebo sequence before the first ascent, 3 from the pla-
cebo–Rhodiola sequence before the first ascent, 2 from
the Rhodiola–placebo sequence during the first ascent,
8 from the Rhodiola–placebo sequence before the sec-
ond ascent, and 5 from the placebo–Rhodiola sequence
before the second ascent. The reasons for withdrawal
included interim business trips (n = 4); infections before
ascent (n = 4, 3 with upper respiratory tract infection, 1
with leg cellulitis); illness of a girlfriend (n = 1); missed
departure due to oversleeping (n = 1); and postpone-
ment of the second trip (n = 6 because of work shift
problems and 5 due to scheduled travel abroad). One
subject in the Rhodiola–placebo sequence developed severe
vertigo and vomiting at 7 h after ascent during the first trip
and was urgently evacuated. Her spouse who also was in
the Rhodiola–placebo sequence descended with her. The
full study protocol was completed by 102 participants. All
participants were exposed to the same temperatures, as
no statistically significant differences were found between
the four ascents (Table 1).
Figure 2 Participant flow diagram.
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None of the participants (54 women, 48 men; average
age, 36.1 ± 10.2 years) went mountaineering regularly, but
none avoided outdoor sports. Participants in both se-
quences (Table 2), Rhodiola–placebo and placebo–Rho-
diola, had similar baseline characteristics (gender, age,
body mass index, blood pressure, blood oxygen content,
heart rate, mountaineering experience, and AMS history
before first period; all P > 0.05).
Period effect and carry-over effect
There was a significant difference in the incidence of
AMS between period 2 (55.9%; 57/102) and period 1




Checkpoint 5 Checkpoint 6 Checkpoint 7
Dec. 03, 2010 8 10 9 0.060
Dec. 12, 2010 9 7 7
Apr. 08, 2011 9 12 12
May 03, 2011 10 14 12
Comparison of temperature among the four ascents was assessed by
Kruskal-Wallis Test.0.45 ~ 0.98). A period effect (P = 0.040) was observed for
the primary outcome, but no carry-over effect was found
(P = 0.877).Major outcome measures
The incidence of AMS was the same among participants
who received Rhodiola extract or placebo (all 62/102,
60.8%). Furthermore, the AMS incidences in the Rhodiola
and placebo groups were 66.7% and 64.8% in period 1,
compared with 55.6% and 56.3% in period 2, respectively
(Figure 3). After adjusting for the period effect, the risk of
AMS in participants taking Rhodiola was 1.03 times that
of participants taking placebo, and no significant differ-
ence was found between the Rhodiola and placebo
groups (95% confidence interval: 0.69–1.52; Table 3).
About half of the participants (50/102) had trip 2 resched-
uled because of a snowstorm, meaning that those taking
Rhodiola had double the planned dosage. Even for these
participants, the AMS incidence in the Rhodiola group
(56.0%, 14/25) was not reduced compared to the placebo
group (48.0%, 12/25).
After adjustment for period effect, between-group
differences in the incidence of severe AMS, headache,
severe headache, SpO2 level and pulse rate at checkpoint
Table 2 Baseline characteristics
Treatment sequences
Characteristic Rhodiola – placebo Placebo – Rhodiola P value
(N = 48) (N = 54)
Male 23 (47.9) 27 (50.0) 0.83
Age, y 35.8 ± 10.0 36.3 ± 10.4 0.84
BMI, kg/m2 22.6 ± 2.9 23.4 ± 3.0 0.17
SpO2*, % 98.8 ± 0.9 98.9 ± 1.0 0.60
Heart rate, beats/min 72.5 ± 8.9 72.2 ± 9.6 0.89
Altitude of residence, m 151.7 ± 105.9 152.7 ± 105.9 0.94
History of mountaineering above 3000 m 0.18
Never 23 (47.9) 36 (66.7)
<10 mountains 20 (41.7) 16 (29.6)
>10 mountains 5 (10.4) 2 (3.7)
History of AMS 7 (14.6) 5 (9.3) 0.54
Continuous variables are presented as mean ± standard deviation, and categorical variables are presented as count (percentage).
BMI, Body mass index.
*SpO2, Oxygen saturation by pulse oximetry at an altitude of 250 m. Heart rate and other demographics were measured during the participant conference
before randomization.
AMS, Acute mountain sickness.
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(Table 3).
Other outcome measures and adverse events
There were no significant differences between Rhodiola
groups and placebo groups for the comparison of the
worst AMS symptom scores and highest LLS scores in
the interval between checkpoints 3 and 8 (all P > 0.05)
(Table 3). The number of subjects requesting medication
for headache/dizziness/nausea (vomiting) was about the
same in both groups (36/20/4 vs. 35/20/3 for Rhodiola
and placebo respectively).Figure 3 AMS occurrence in 2 periods. The incidence of AMS was
65.7% (67/102) in period 1 and 55.9% (57/102) in period 2 (OR: 0.66,
95% CI: 0.45 − 0.98). There were no between-group differences in
either period.During the 7-day period prior to ascent, adverse events
were rare. All were rare, mild and lasted less than two
days; therefore, no participant needed to stop taking the
study drugs prior to ascent (Table 4).
Sensitivity analysis
In total, there were fifteen subjects who attended mountain
climbing during period 1 but were absent during period
2 (Figure 2). To evaluate the impact of dropout on the
efficacy for the Rhodiola arm compared to the placebo
arm, two scenario analyses were carried out in order to fill
in the missing values for AMS occurrence. In the first
scenario, the missing values were assumed to be in favor
of Rhodiola in preventing AMS. The odds ratio was 0.88
and 95% confidence interval contains 1 (0.6 − 1.3, P = 0.49).
In the second scenario which is in favor of the placebo in
preventing AMS, and odds ratio was 1.4 and 95% confi-
dence interval contains 1 (0.94 − 2.11, P = 0.10). In either
scenario, Rhodiola was not effective in preventing AMS
(Figure 4).
Assessment of blinding
After the second trip, all participants were asked to guess
the trip in which they had taken Rhodiola; 49% (50/102)
guessed correctly, indicating that the participants iden-
tified the treatment period during which they received
Rhodiola or placebo only by chance.
Discussion
R. crenulata extract was not effective in reducing the inci-
dence or severity of AMS when compared with placebo
and failed to show a protective benefit for any outcome
Table 3 Outcomes
Outcome
Rhodiola Placebo Odds ratio/difference Adjusted
(N=102) (N=102) (95% CI) P value
Primary endpoint
AMSa 62 (60.8) 62 (60.8) 1.02 (0.69, 1.52) †† 0.90
Secondary endpoint
Severe AMSb 36 (35.3) 30 (29.4) 1.42 (0.90, 2.25) †† 0.13
Headache 81 (79.4) 78 (77.5) 1.17 (0.75, 1.83) †† 0.48
Severe headachec 33 (32.4) 30 (29.4) 1.16 (0.71, 1.89) †† 0.55
SpO2, %
d 88.6 ± 3.9 88.6 ± 4.3 –0.13 (–0.93, 0.66) ‡‡ 0.74
ΔSpO2, % 9.6 ± 3.8 9.5 ± 4.2 0.16 (–0.65, 0.97)
‡‡ 0.70
Pulse rate, /mine 99.2 ± 14.6 99.8 ± 14.2 –0.30 (–2.61, 2.02) ‡‡ 0.80
Other clinical measures
AMS symptoms scoref
Headache 1.17 ± 0.81 1.13 ± 0.83 0.05 (-0.10, 0.20) ‡‡ 0.50
Dizziness 0.87 ± 0.82 0.79 ± 0.79 0.09 (-0.06, 0.25) ‡‡ 0.29
Weakness 0.94 ± 0.81 0.99 ± 0.84 –0.02 (–0.17, 0.13) ‡‡ 0.81
Vomiting 0.52 ± 0.70 0.41 ± 0.62 0.12 (–0.01, 0.25) ‡‡ 0.08
Sleep 1.45 ± 0.99 1.55 ± 0.96 –0.07 (–0.29, 0.14) ‡‡ 0.49
LLS score 3.84 ± 2.49 3.77 ± 2.54 0.19 (-0.27, 0.55) ‡‡ 0.51
For each outcome, data were grouped into two datasets (one for Rhodiola and one for placebo) to create a data summary. Categorical outcomes are presented as
count (percentage), and continuous outcomes as mean ± standard deviation. The treatment effect is presented in the column “Odds ratio/difference (95% CI)”.
Odds ratio is used for categorical outcomes and defined as Rhodiola versus placebo, while difference is used for continuous outcomes and defined as Rhodiola
minus placebo. The generalized linear models with generalized estimating equations method, assuming logit/ identity link as appropriate and unstructured
correlation, was used to obtain the results after adjustment of period effects.
a Lake Louise score (LLS score) ≥3 with headache and at least one other symptom was defined as AMS. At each period, occurrence of AMS during checkpoints 3
to 8 was defined as AMS.
b AMS and LLS score ≥5.
c Defined as headache score of >1 on the headache item of LLS (ascending scale of 0–3 for severity).
d SpO2, oxygen saturation by pulse oximetry (SpO2) at checkpoint 4 (3100 m).
ΔSpO2, the difference between checkpoints 1 and 4 (SpO2 at checkpoint 1 – SpO2 at checkpoint 4).
e Pulse rate was measured at checkpoint 4 (3100 m).
f All symptoms in AMS are defined as the worst score in the interval between checkpoints 3 and 8.
†† odds ratio.
‡‡ difference.
Table 4 Adverse events in groups receiving prophylactic
agents for AMS
Adverse event Rhodiola (n = 102) Placebo (n = 102)
Difficulty in falling asleep 1 (0.98) 1 (0.98)
Light sleep 3 (2.94) 1 (0.98)
Dizziness 2 (1.96) 0 (0.00)
Drowsiness 2 (1.96) 0 (0.00)
Pruritus 1 (0.98) 1 (0.98)
Dry hand 1 (0.98) 0 (0.00)
Abdominal distension 1 (0.98) 0 (0.00)
General soreness 1 (0.98) 0 (0.00)
Dry mouth 0 (0.00) 3 (2.94)
Headache 0 (0.00) 2 (1.96)
Palpitation 0 (0.00) 2 (1.96)
Flushed face 0 (0.00) 1 (0.98)
Increased urination 0 (0.00) 1 (0.98)
Data are presented as count (%).
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there was a period effect but no carry-over effect. AMS
occurred significantly less frequently on the second moun-
taineering trip (65.7% vs. 55.9%; P = 0.040), regardless of
treatment. Since most participants (58%) had no high-
altitude mountaineering experience prior to the first trip,
the first trip experience helped them adapt to conditions
on the second trip in period 2. Inadequate high-altitude
mountaineering experience was proven to be an inde-
pendent risk factor for AMS [36-39]. In Gaillard’s study,
the understanding and awareness of AMS among trekkers
reduced the incidence of AMS [40]. Also, Vardy et al. sug-
gested that AMS is less likely to take place with a correct
awareness of its symptoms and prevention [41]. In our
study, the participants filled the Lake Louise self-report
questionnaire at 10 checkpoints during mountaineering,
so they had a comprehensive awareness of high altitude
experience and AMS symptoms after the first period of
mountaineering. They also shared experiences and
Figure 4 Sensitivity analysis. Data was presented as adjusted odds ratio (AOR) and 95% confidence interval (CI). Comparison between Rhodiola
arm and placebo arm was analyzed by generalized linear models with generalized estimating equations. Regardless of any extreme scenarios,
Rhodiola was not effective in preventing AMS. *: significant difference statistically.
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pact activity at high altitude. Therefore, the participants
had a significantly superior awareness of symptoms and
prevention for AMS in the second period than in the first
period of mountaineering. Also, no period effect was ob-
served among the experienced participants in our study.
Thus, this phenomenon could be classified as a learning
effect. The weather, warmer during period 2, could be the
other explanation for the period effect. Our trial was de-
signed conservatively to avoid any possible bias against R.
crenulata: we used a high dose of this agent, a longer
period of drug preloading, and a steep ascent profile from
the sea level. During the mountaineering trips, the follow-
ing variables were controlled: rate of ascent, path, food
type, and sleep altitude/environment.
In the present study, the environmental and medical
resources available to study AMS were limited. We de-
signed our study as a crossover trial for a key reason.
Because each participant serves as his or her own control,
it skillfully controls for the inherent individual suscepti-
bility to AMS. Each person has his or her own personal
tolerance for altitude change, and consequently, we cal-
culated the percentage change of outcomes from his or
her baseline to evaluate the effect of intervention or
association with possible factors in parallel design. Using
crossover design enabled us to measure the effect of inter-
vention exactly, regardless of individual susceptibility. This
design also had the benefits of increasing statistical power,
given the limited sample size, and efficient control of the
influence of confounding covariates.
Our study had several limitations. First, only 102 of
the original 125 participants completed both trips. How-
ever, the statistical analyses were still adequately powered
for three reasons: (1) the incidence of AMS was higher
than what we had hypothesized using data generated inour previous survey [36]. This was because most of our
participants were inexperienced mountaineers, and their
rate of controlled ascent was significantly higher than that
in the previous study (4 h vs. 1–2 days). The participants
were requested not to take acetazolamide or other possible
prophylactic medications used by trekkers before moun-
taineering in previous surveys. (2) The sample size was es-
timated using the assumption that Rhodiola would reduce
the incidence of AMS by 11% (36% to 25%) compared to
placebo, but the results showed no difference between tak-
ing Rhodiola and placebo. Based on the data obtained in
the present study, a sample of infinite size would be re-
quired to prove that Rhodiola had a significant prophylac-
tic effect. (3) The sensitivity analysis showed that Rhodiola
was not effective in preventing AMS regardless of the sce-
narios proposed (Figure 4). The second limitation is that
half of the participants had a rescheduled second trip and
they therefore took the study medication (or placebo) for
7 days before ascent and then on the first morning of as-
cent, for 8 days. Although they did not reach an altitude
where AMS might be expected, they took study medication
for 8 out of 9 days, and then they began medication once
again 4 weeks later. Although these participants took
double dosage of Rhodiola, their AMS incidence was not
reduced. The third limitation is that the Rhodiola extract
purified from the rhizome of R. crenulata was used to
assure high concentration of active ingredients (2.38%
salidroside and 0.44% p-tyrosol) in this study. However,
the active ingredients for preventing AMS could have
been lost during extraction and purification. Many Chinese
tourists drink a decoction of Rhodiola rhizome to prevent
AMS. The results of the present study do not exclude the
possibility that this R. crenulata decoction may have a
preventive effect on AMS. Last, only one dosage and one
Rhodiola species were tested. Higher dosage or extracts
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kirilowii, Rhodiola sachalinensis, and Rhodiola algida,
might be effective.
Studies have investigated different pharmacologic inter-
ventions to prevent AMS. Acetazolamide is effective for
the prevention of AMS but it may be associated with
paresthesias. Sumatriptan and gabapentin are beneficial
but require further study [5]. Antioxidants magnesium,
Ginkgo biloba and Coca leaf products were not efficacious
[5,17]. In the Himalayan region, China, and Andean re-
gion of South America, using traditional applications
of herbs for anti-high altitude illness is more common
than using doctor prescription. For example, Coca leaf
products were used more often among 62.8% of the
surveyed travelers than acetazolamide prophylaxis (16.6%)
for prevention, or other non-pharmacologic measures
[17]. Similar in China, 7% of 247 Chinese travelers on
Qinghai-Tibet railroad took Rhodiola as a prophylaxis for
AMS, but none used acetazolamide or dexamethasone,
except one who had asthma [32]. It was shown that coca
leaf products did not prevent AMS, but increased the
chance of AMS occurrence. Therefore, complementary
and alternative medicines are omnipresent and popular,
and should not be dismissed as “non-medications”.
Our study is the first randomized, double-blind and con-
trolled study of R. crenulata extract for AMS prophylaxis
in humans though the current data does not demonstrate
any prophylactic effects. Further studies will be needed to
demonstrate the efficacy of R. crenulata decoction or other
Rhodiola species in AMS prevention.
Conclusions
This randomized double-blind placebo control crossover
trial demonstrated that the R. crenulata extract was not
effective in reducing the incidence or severity of AMS.
R. crenulata extract should not be recommended as a
prophylactic for AMS.
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